Please use this identifier to cite or link to this item:
|Title:||Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer|
De Campos, E. S.
Bell, D. R.
Steward, W. P.
Vansteenkiste, J. F.
Ewers, S. B.
|Publisher:||Cancer Research UK, Nature Publishing Group|
|Citation:||British Journal of Cancer (1999) 80, 396–402.|
|Abstract:||Anaemia commonly occurs in cancer patients receiving chemotherapy, often necessitating blood transfusion. This multicentre study was designed to evaluate the efficacy and safety of epoetin α in preventing the decline in haemoglobin (Hb) level, and to determine whether the transfusion requirement could be reduced, in patients receiving 4–6 cycles of primarily platinum-based combination cyclic chemotherapy for small cell lung cancer (SCLC). A total of 130 non-anaemic SCLC patients were randomized to receive no additional treatment (n = 44), epoetin α 150 IU kg–1 subcutaneously (s.c.) three times a week (n = 42) or 300 IU kg–1 s.c. three times a week (n = 44). Reductions in epoetin α dosage were made during the study if Hb level increased to >15 g dl–1. The mean weekly dosage was 335 and 612 IU kg–1, respectively, in the two active treatment groups. Significantly fewer (P < 0.05) epoetin α-treated patients experienced anaemia (Hb < 10 g dl–1) during the course of chemotherapy (300 IU kg–1, 39%; 150 IU kg–1, 48%; untreated, 66%). This was reflected in the significantly lower number of treated patients transfused [300 IU kg–1, 20% (P < 0.001); 150 IU kg–1, 45% (P < 0.05); untreated, 59%]. Epoetin α was well-tolerated, and there was no evidence of sustained, clinically significant, hypertension. In summary, epoetin α is effective and well-tolerated in maintaining Hb level and reducing transfusion requirement in patients undergoing cyclic chemotherapy for SCLC.|
|Rights:||Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/|
|Appears in Collections:||Published Articles, Dept. of Cancer Studies and Molecular Medicine|
Files in This Item:
|Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer..pdf||Publisher version||128.75 kB||Adobe PDF||View/Open|
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.